Post Stroke Arm Spasticity
Conditions
Brief summary
The objective of this non-interventional study is to evaluate clinical effectiveness and cost effectiveness of Dysport within the reimbursement scheme called drug programme funded by Polish National Health Fund (NHF) for patients with post stroke ULS. The study is designed to collect data in patients scheduled to receive Dysport treatment in a drug programme, based on routine treatment of subject with ULS.
Interventions
None listed
Sponsors
Ipsen
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥ 18 years of age. * A history of ischemic or haemorrhagic stroke before minimum 3 months prior to the inclusion into drug programme, documented by discharge from the hospital. * Post-stroke spasticity of confirmed upper extremity moderate or higher (the result of the modified Ashworth scale - MAS ≥ 2) in at least one muscle group. * Classification of the patient into the programme occurs when a patient has a designated date of commencement of medical rehabilitation confirmed by the providing rehabilitation services. * Drug administration needs to take place no earlier than three weeks before the start of medical rehabilitation. * Written informed consent given by patient before any occurrence of study related procedure. * Patient has been already included in a NHF Dysport programme.
Exclusion criteria
* Severe dysphagia and respiratory disorders. * Pregnancy * Myasthenia gravis and myasthenic syndrome - based on neurological examination (additional tests only in justified cases). * Generalized symptoms of infection * The presence of inflammation within the planned sites of administration. * Fixed contractures in the soft tissues and joints. * Dementia medium or deep cycle (score on mini mental state examination (MMSE) equal to or less than 18 points).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Investigator and patient Clinical Global Impression of Improvement (CGI-I) | Change from baseline (visit 1) to visit 3 (visits occur every 3-4 months, during approximately 9 months of observation) | Clinical Global Impression of Improvement (CGI-I) scale: 7-point scale, ranging from 1 (very much improved) to 7 (very much worse), with a score of 4 indicating no change. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Global assessment of spasticity by Modified Ashworth Scale (MAS) | Visits 1, 2 and 3 (visits occur every 3-4 months, during approximately 9 months of observation) | MAS - spasticity scores at each joint: shoulder, elbow, wrist, finger, thumb |
| Measurement of upper limb muscle weakness by Medical Research Council (modified MRC) scale for muscle strength | Visits 1, 2 and 3 (visits occur every 3-4 months, during approximately 9 months of observation) | — |
| To document cost of treatment with Dysport in these patients | Visits 1, 2 and 3 (visits occur every 3-4 months, during approximately 9 months of observation) | Direct costs associated with the administration of Dysport will include the dose of Dysport, interval between reinjections, cost of healthcare resources: needles, syringes, identification techniques of the muscles. |
Countries
Poland
Outcome results
None listed